Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04497987
Previous Study | Return to List | Next Study

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04497987
Recruitment Status : Completed
First Posted : August 4, 2020
Last Update Posted : July 6, 2021
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
AbCellera Biologics Inc.
Shanghai Junshi Bioscience Co., Ltd.
Information provided by (Responsible Party):
Eli Lilly and Company

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19). Facility staff and residents in contracted skilled nursing and assisted living facility networks with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. Participation could last up to 25 weeks and may include up to 19 visits.

Condition or disease Intervention/treatment Phase
COVID-19 SARS-CoV2 Drug: LY3819253 Drug: Placebo Drug: LY3832479 Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1374 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study
Actual Study Start Date : August 2, 2020
Actual Primary Completion Date : January 16, 2021
Actual Study Completion Date : May 20, 2021
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: LY3819253 (Part 1)
LY3819253 administered intravenously (IV).
 Drug: LY3819253
Administered IV.
Other Names:
  • LY-CoV555
  • Bamlanivimab
Placebo Comparator: Placebo (Part 1)
Placebo administered IV.
 Drug: Placebo
Administered IV.
Experimental: LY3819253 (Part 2 - Prevention)
LY3819253 administered IV to prevention cohort.
 Drug: LY3819253
Administered IV.
Other Names:
  • LY-CoV555
  • Bamlanivimab
Experimental: LY3819253 + LY3832479 (Part 2 - Prevention)
LY3819253 + LY3832479 administered IV to prevention cohort.
 Drug: LY3819253
Administered IV.
Other Names:
  • LY-CoV555
  • Bamlanivimab

Drug: LY3832479
Administered IV.
Other Names:
  • LY-CoV016
  • Etesevimab
Placebo Comparator: Placebo (Part 2 - Prevention)
Placebo administered IV to prevention cohort.
 Drug: Placebo
Administered IV.
Experimental: LY3819253 (Part 2 - Treatment)
LY3819253 administered IV to treatment cohort.
 Drug: LY3819253
Administered IV.
Other Names:
  • LY-CoV555
  • Bamlanivimab
Experimental: LY3819253 + LY3832479 (Part 2 - Treatment)
LY3819253 + LY3832479 administered IV to treatment cohort.
 Drug: LY3819253
Administered IV.
Other Names:
  • LY-CoV555
  • Bamlanivimab

Drug: LY3832479
Administered IV.
Other Names:
  • LY-CoV016
  • Etesevimab
Experimental: LY3819253 (Part 3 - Treatment)
LY3819253 administered IV.
 Drug: LY3819253
Administered IV.
Other Names:
  • LY-CoV555
  • Bamlanivimab
Experimental: LY3819253 + LY3832479 (Part 3 - Treatment)
LY3819253 + LY3832479 administered IV.
 Drug: LY3819253
Administered IV.
Other Names:
  • LY-CoV555
  • Bamlanivimab

Drug: LY3832479
Administered IV.
Other Names:
  • LY-CoV016
  • Etesevimab


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of Participants with COVID-19 within 21 Days of Detection [ Time Frame: Baseline through Week 8 ]
    Percentage of Participants with COVID-19 within 21 Days of Detection


Secondary Outcome Measures :
  1. Percentage of Participants with Moderate or Worse Severity COVID-19 within 21 Days of Detection [ Time Frame: Baseline through Week 8 ]
    Percentage of Participants with Moderate or Worse Severity COVID-19 within 21 Days of Detection

  2. Percentage of Participants with SARS-CoV-2 [ Time Frame: Baseline through Week 4 ]
    Percentage of Participants with SARS-CoV-2

  3. Percentage of Participants Who are Hospitalized or Have Died due to COVID-19 [ Time Frame: Week 8 ]
    Percentage of Participants Who are Hospitalized or Have Died due to COVID-19

  4. Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death [ Time Frame: Week 8 ]
    Percentage of Participants who Experience COVID-19-Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death

  5. Percentage of Participants Who Die Due to COVID-19 [ Time Frame: Week 8 ]
    Percentage of Participants Who Die Due to COVID-19

  6. Pharmacokinetics (PK): Mean Concentration of LY3819253 Administered Alone [ Time Frame: Day 29 ]
    PK: Mean Concentration of LY3819253 Administered Alone

  7. PK: Mean Concentration of LY3819253 in the Presence of LY3832479 [ Time Frame: Day 29 ]
    PK: Mean Concentration of LY3819253 in the Presence of LY3832479

  8. PK: Mean Concentration of LY3832479 in the Presence of LY3819253 [ Time Frame: Day 29 ]
    PK: Mean Concentration of LY3832479 in the Presence of LY3819253


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Part 1 and Part 2: Resident or facility staff in a skilled nursing or assisted living facility with at least one confirmed case of SARS-CoV-2 detection less than or equal to (≤)7 days prior to randomization
  • Are men or non-pregnant women who agree to contraceptive requirements
  • Agree to the collection of nasal, mid-turbinate, oropharyngeal, and nasopharyngeal swabs, and venous blood as specified in the schedule of activities
  • Have venous access sufficient to allow intravenous infusions and blood sampling
  • The participant or legally authorized representative give signed informed consent

  • Part 3 only: Resident or staff in a skilled nursing or assisted living facility who satisfy at least one of the following at the time of screening

    • Are greater than or equal to (≥) 65 years of age
    • Have a body mass index (BMI) ≥ 35
    • Have chronic kidney disease
    • Have type 1 or type 2 diabetes
    • Have immunosuppressive disease
    • Are currently receiving immunosuppressive treatment, or

    • Are ≥ 55 years of age AND have

      • cardiovascular disease, OR
      • hypertension, OR
      • chronic obstructive pulmonary disease or other chronic respiratory disease
  • Positive SARS-CoV-2 test and infusion within 10 days of symptom onset, OR positive SARS-CoV-2 test and infusion within 10 days of testing if asymptomatic

Exclusion Criteria:

  • Parts 1 and 2:

    • Recovered from confirmed COVID-19 disease or asymptomatic infection
    • Prior history of a positive SARS-CoV-2 serology test
    • History of convalescent COVID-19 plasma treatment
    • Participation in a previous SARS-CoV-2 vaccine trial or received an approved SARS-CoV-2 vaccine
    • Previous receipt of SAR-CoV-2-specific monoclonal antibodies
  • Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04497987


Locations
Show Show 27 study locations
Sponsors and Collaborators
Eli Lilly and Company
National Institute of Allergy and Infectious Diseases (NIAID)
AbCellera Biologics Inc.
Shanghai Junshi Bioscience Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT04497987    
Other Study ID Numbers: 18063
J2X-MC-PYAD ( Other Identifier: Eli Lilly and Company )
CoVPN #3501 ( Other Identifier: National Institute of Allergy and Infectious Diseases (NIAID) )
First Posted: August 4, 2020    Key Record Dates
Last Update Posted: July 6, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Eli Lilly and Company:
Prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Infections
Respiratory Tract Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases